92 related articles for article (PubMed ID: 10350341)
1. Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy.
Tormo M; Terol MJ; Marugán I; Solano C; Benet I; Garcia-Conde J
Leuk Lymphoma; 1999 Jun; 34(1-2):137-42. PubMed ID: 10350341
[TBL] [Abstract][Full Text] [Related]
2. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.
Hagemeister FB; Cabanillas F; Velásquez WS; Meistrich ML; Liang JC; McLaughlin P; Redman JR; Romaguera JE; Rodríguez MA; Swan F
Semin Oncol; 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40. PubMed ID: 2259922
[TBL] [Abstract][Full Text] [Related]
3. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.
Hagemeister FB; Fuller L; McLaughlin P; Rodriguez M; Romaguera J; Swan F; Cabanillas F
Ann Oncol; 1992 Sep; 3 Suppl 4():87-90. PubMed ID: 1450086
[TBL] [Abstract][Full Text] [Related]
4. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
[TBL] [Abstract][Full Text] [Related]
5. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.
Hagemeister FB; Purugganan R; Podoloff DA; Hess M; Rodriguez MA; McLaughlin P; Swan F; Romaguera JE; Cabanillas F
Ann Oncol; 1994; 5 Suppl 2():59-63. PubMed ID: 8204521
[TBL] [Abstract][Full Text] [Related]
6. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.
Meistrich ML; Wilson G; Mathur K; Fuller LM; Rodriguez MA; McLaughlin P; Romaguera JE; Cabanillas FF; Ha CS; Lipshultz LI; Hagemeister FB
J Clin Oncol; 1997 Dec; 15(12):3488-95. PubMed ID: 9396402
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.
Hagemeister FB; Purugganan R; Fuller L; McLaughlin P; Swan F; Romaguera J; Rodriguez M; Cabanillas F
Semin Hematol; 1994 Apr; 31(2 Suppl 3):36-43. PubMed ID: 8073308
[No Abstract] [Full Text] [Related]
8. Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP).
Dubey P; Wilson G; Mathur KK; Hagemeister FB; Fuller LM; Ha CS; Cox JD; Meistrich ML
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):609-17. PubMed ID: 10701740
[TBL] [Abstract][Full Text] [Related]
9. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity.
Liang JC; Bailey NM; Gabriel GJ; Kattan MW; Wang RY; Hagemeister FB; Cabanillas FF; Fuller LM
Leuk Lymphoma; 1993 Apr; 9(6):503-8. PubMed ID: 7687918
[TBL] [Abstract][Full Text] [Related]
10. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
11. Are alkylating agents a necessary component in the therapy of Hodgkin's disease.
Hagemeister FB
Leuk Lymphoma; 1993; 10 Suppl():91-7. PubMed ID: 7683230
[TBL] [Abstract][Full Text] [Related]
12. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
13. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
14. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
[TBL] [Abstract][Full Text] [Related]
16. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
17. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
20. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
